Gilead Sciences, Inc.

NASDAQ:GILD   3:59:59 PM EDT
59.97
-0.82 (-1.35%)
4:19:00 PM EDT: $59.91 -0.06 (-0.10%)
Products

FDA Says Remdesivir EUA Letter Of Authorization, Reissued Oct 16

Published: 10/16/2020 23:38 GMT
Gilead Sciences Inc (GILD) - FDA, in Letter to Gilead, Says Remdesivir Eua Letter of Authorization, Reissued October 16, Remdesivir for Certain Hospitalized Covid-19 Patients.
FDA Says Reissuing Oct 1 Letter to Clarify That Alternate Care Site Meeting Certain Criteria is Considered “inpatient Hospital Setting” for Scope of Eua.
FDA Says Authorizing Emergency Use of Veklury for Treatment of Covid-19, As Described in "scope of Authorization" Section of Reissued Letter.
FDA Says Veklury May Be Effective,known & Potential Benefits of Veklury Outweigh Known & Potential Risks in Treatment of Patients Hospitalized With Covid19.